Protein-Based Drug Delivery in Brain Tumor Therapy

被引:3
作者
Hwang, Hae Hyun [1 ,2 ,3 ]
Lee, Dong Yun [1 ,2 ,3 ]
机构
[1] Hanyang Univ, Coll Engn, Dept Bioengn, Seoul, South Korea
[2] Hanyang Univ, BK21 PLUS Future Biopharmaceut Human Resource Tra, Seoul, South Korea
[3] Hanyang Univ, Inst Nano Sci & Technol INST, Seoul, South Korea
来源
BIOINSPIRED BIOMATERIALS: ADVANCES IN TISSUE ENGINEERING AND REGENERATIVE MEDICINE | 2020年 / 1249卷
基金
新加坡国家研究基金会;
关键词
Brain tumor; Drug delivery; Oral administration of protein-based drug; Drug stability; GLYCOPROTEIN INHIBITOR HM-30181; BLOOD-BRAIN; P-GLYCOPROTEIN; IN-VITRO; ALBUMIN NANOPARTICLES; BARRIER PERMEABILITY; ORAL BIOAVAILABILITY; PLGA NANOPARTICLES; PACLITAXEL TAXOL; TRANSFERRIN;
D O I
10.1007/978-981-15-3258-0_13
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Despite the use of active surgeries, radiotherapy, and chemotherapy in clinical practice, brain tumors are still a difficult health problem due to their rapid development and poor prognosis. To treat brain tumors, various nanoparticles can be used to target effective physiological conditions based on continuously changing vascular characteristics and microenvironments to promote effective brain tumor-targeting drug delivery. In addition, a brain tumor-targeting drug delivery system that increases drug accumulation in the brain tumor area and reduces toxicity in the normal brain and peripheral tissues is needed. However, the blood-brain barrier is a big obstacle for drug delivery to the brain. In this chapter, we provide a broad overview of brain drug delivery and current strategies over the last few years. In addition, several questions have been reconsidered, such as whether nanoparticles believed to be delivered to the brain can pass through the blood-brain barrier, whether the drug is delivered to the target site, and what brain tumor treatment is possible.
引用
收藏
页码:203 / 221
页数:19
相关论文
共 138 条
[51]   Diatoms: A Novel Source for the Neurotoxin BMAA in Aquatic Environments [J].
Jiang, Liying ;
Eriksson, Johan ;
Lage, Sandra ;
Jonasson, Sara ;
Shams, Shiva ;
Mehine, Martin ;
Ilag, Leopold L. ;
Rasmussen, Ulla .
PLOS ONE, 2014, 9 (01)
[52]   Surface modified PLGA nanoparticles for brain targeting of Bacoside-A [J].
Jose, S. ;
Sowmya, S. ;
Cinu, T. A. ;
Aleykutty, N. A. ;
Thomas, S. ;
Souto, E. B. .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 63 :29-35
[53]  
Joseph A, 2007, AM J HLTH SYSTEM PHA, V64
[54]   The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles? [J].
Juillerat-Jeanneret, Ludenne .
DRUG DISCOVERY TODAY, 2008, 13 (23-24) :1099-1106
[55]   Neuropharmacokinetic evaluation of lactoferrin-treated indinavir-loaded nanoemulsions: remarkable brain delivery enhancement [J].
Karami, Zahra ;
Zanjani, Mohammad Reza Saghatchi ;
Rezaeeb, Saeed ;
Rostamizadeh, Kobra ;
Hamidi, Mehrdad .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2019, 45 (05) :736-744
[56]   Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art [J].
Karim, Reatul ;
Palazzo, Claudio ;
Evrard, Brigitte ;
Piel, Geraldine .
JOURNAL OF CONTROLLED RELEASE, 2016, 227 :23-37
[57]   Albumin nanostructures as advanced drug delivery systems [J].
Karimi, Mahdi ;
Bahrami, Sajad ;
Ravari, Soodeh Baghaee ;
Zangabad, Parham Sahandi ;
Mirshekari, Hamed ;
Bozorgomid, Mahnaz ;
Shahreza, Somayeh ;
Sori, Masume ;
Hamblin, Michael R. .
EXPERT OPINION ON DRUG DELIVERY, 2016, 13 (11) :1609-1623
[58]  
Kemper EM, 2003, CLIN CANCER RES, V9, P2849
[59]   Regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cell-binding domain of fibronectin [J].
Kim, S ;
Bell, K ;
Mousa, SA ;
Varner, JA .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (04) :1345-1362
[60]   Protein Interactions at Endothelial Junctions and Signaling Mechanisms Regulating Endothelial Permeability [J].
Komarova, Yulia A. ;
Kruse, Kevin ;
Mehta, Dolly ;
Malik, Asrar B. .
CIRCULATION RESEARCH, 2017, 120 (01) :179-206